189 filings
Page 5 of 10
6-K/A
NLSP
NLS Pharmaceutics Ltd
16 Sep 22
Current report (foreign) (amended)
4:30pm
6-K
NLSP
NLS Pharmaceutics Ltd
8 Sep 22
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
6:08am
6-K
NLSP
NLS Pharmaceutics Ltd
23 Aug 22
Report of Foreign Private Issuer
4:21pm
6-K
NLSP
NLS Pharmaceutics Ltd
28 Jul 22
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
8:31am
6-K
NLSP
NLS Pharmaceutics Ltd
21 Jul 22
NLS Pharmaceutics Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia
8:31am
EFFECT
NLSP
NLS Pharmaceutics Ltd
22 Jun 22
Notice of effectiveness
12:15am
CORRESP
NLSP
NLS Pharmaceutics Ltd
17 Jun 22
Correspondence with SEC
12:00am
UPLOAD
NLSP
NLS Pharmaceutics Ltd
16 Jun 22
Letter from SEC
12:00am
F-1
NLSP
NLS Pharmaceutics Ltd
10 Jun 22
Registration statement (foreign)
4:43pm
6-K
NLSP
NLS Pharmaceutics Ltd
10 Jun 22
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
4:30pm
6-K
NLSP
NLS Pharmaceutics Ltd
6 Jun 22
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
8:02am
6-K
NLSP
NLS Pharmaceutics Ltd
3 Jun 22
Report of Foreign Private Issuer
5:00pm
6-K
NLSP
NLS Pharmaceutics Ltd
2 Jun 22
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience® for the Treatment of Narcolepsy
8:30am
6-K
NLSP
NLS Pharmaceutics Ltd
1 Jun 22
Report of Foreign Private Issuer
4:30pm
6-K
NLSP
NLS Pharmaceutics Ltd
11 May 22
Report of Foreign Private Issuer
5:00pm
6-K
NLSP
NLS Pharmaceutics Ltd
4 May 22
NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience® Phase 2a Clinical Trial for Patients with Narcolepsy
9:01am
6-K
NLSP
NLS Pharmaceutics Ltd
27 Apr 22
NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering
6:04am
6-K
NLSP
NLS Pharmaceutics Ltd
25 Apr 22
Report of Foreign Private Issuer
5:25pm
6-K
NLSP
NLS Pharmaceutics Ltd
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
424B5
NLSP
NLS Pharmaceutics Ltd
14 Apr 22
Prospectus supplement for primary offering
4:48pm